The <scp>340B</scp> Drug Pricing Program and Management of Advanced Prostate Cancer
There was no association between a region's 340B penetration and use of a targeted therapy. Furthermore, although the use of a targeted therapy decreased with increased SVI, the 340B penetration of a region did not reduce this gap.
Authors
- Brent K. Hollenbeck (ORCID: https://orcid.org/0000-0003-4840-1260)
- Christopher Dall (ORCID: https://orcid.org/0000-0002-2207-0531)
- Kassem Faraj (ORCID: https://orcid.org/0000-0002-2130-0446)
- Megan E.V. Caram (ORCID: https://orcid.org/0000-0003-1597-5428)
- Vahakn B. Shahinian (ORCID: https://orcid.org/0000-0003-3280-7821)
- Mary Oerline (ORCID: https://orcid.org/0000-0002-0264-6951)
- Arnav Srivastava (ORCID: https://orcid.org/0000-0002-9772-1415)
- Samuel R. Kaufman
Institutions
- University of Michigan (US)
- Massachusetts General Hospital (US)
- Health Services Research & Development (US)
- VA Ann Arbor Healthcare System (US)
- VA Center for Clinical Management Research (US)
Publication Details
- Journal
- Cancer Medicine
- Published
- 2024-12-30
- DOI
- https://doi.org/10.1002/cam4.70552
- Primary Topic
- Prostate Cancer Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Cancer Institute